期刊文献+

^(89)Sr治疗前列腺癌骨转移疗效分析 被引量:11

Strontium-89:A Desirable Therapeutic for Bone Metastases of Prostate Cancer
下载PDF
导出
摘要 目的:评价89Sr治疗前列腺癌骨转移的临床疗效。方法:对确认前列腺癌骨转移伴骨痛的116例患者,行双侧睾丸切除术+内分泌药物+89Sr治疗。89Sr治疗静脉给药,剂量1.48~2.22MBq(40~60μCi)/kg。随访分析临床疗效。结果:①33.6%的患者食欲明显改善,56.0%的患者睡眠明显改善,61.2%的患者止痛药用量显著减少;②骨转移性疼痛缓解总有效率为83.6%,24.1%的患者完全缓解;③骨痛缓解开始出现时间3~21d,平均10.2d;④骨痛缓解维持时间3~12个月,平均5.3个月;⑤31.9%的患者出现"闪烁"痛;⑥生活质量(KPS评分)平均升高20.0%;⑦治疗后18.1%的患者血液白细胞由正常水平下降至3.0~3.9×106/L(Ⅰ度血液毒性反应);⑧随访53例骨显像,治疗后73.6%(39例)骨转移灶数目较治疗前明显减少,18.9%(10例)稳定,7.5%(4例)恶化。结论:89Sr治疗能有效抑制骨转移,缓解骨痛,改善生存质量,不良反应轻,是前列腺癌骨转移性疼痛较理想的治疗方法。 Objective: To evaluate the efficacy of strontium-89 ( 89 Sr) in the treatment of painful bone metastases of prostate cancer. Methods: A total of 116 patients with painful bone metastases of prostate cancer received bilateral orchectomy and incretion, followed by intravenous injection of ^89Sr at the dose of 1.48-2.22 MBq (40-60uCi)/kg. The clinical effects were evaluated by follow-up analysis. Results : After the 89 Sr treatment, appetite and sleep were evidently improved in 33.6% and 56.0% of the patients respectively, the applied dose of anodyne reduced in 61.2% , pain alleviated in 83.6% , with an absolute palliation rate of 24.1%. Pain relief started at 3-21 ( 10.2 -+6.5) days and lasted 3-12 (5.3 ±2.2) months. Flare ache occurred in 31.9% of the patients. Compared with pre-treatment, the mean score on Kamofsky's performance status (KPS) was 20.0% higher, and the WBC count decreased to 3.0-3.9×10^6/L in 18.1% of the patients. Whole body bone seintigrapby of 53 followed-up patients showed that 39 (73.6%) of them exhibited an obvious decrease in the number of metastases, 10 ( 18.9% ) remained in a stabilized state and only 4 (7.5%) deteriorated. Conclusion: ^89Sr, capable of inhibiting bone metastasis, palliating pain and improving the quality of life with few adverse effects, can be used as a desirable therapeutic for painful bone metastases of prostate cancer.
出处 《中华男科学杂志》 CAS CSCD 2008年第9期819-822,共4页 National Journal of Andrology
关键词 ^89锶 前列腺癌 骨转移性疼痛 放射疗法 strontium-89 prostate cancer painful bone metastasis radiotherapy
  • 引文网络
  • 相关文献

参考文献9

  • 1Payne R. Pain management in the patient with prostate cancer [ J ]. Cancer, 1993, 71 ( 3 Suppl) : 1131-1137.
  • 2Pons F, Herranz R, Garcia A, et al. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer[ J ]. Eur J Nuel Med, 1997, 24 (10) : 1210-1214.
  • 3陈雪红,钟甘平,王正江,袁耿彪,王家吉,冯建中,李西焕.^(89)SrCl_2对老年人前列腺癌转移性骨痛的疗效观察[J].中华老年医学杂志,2003,22(12):720-722. 被引量:4
  • 4任晓敏,应俊,姚德鸿,叶传扬,蒋跃庆.前列腺癌骨转移性疼痛的综合治疗[J].中华男科学杂志,2004,10(3):188-190. 被引量:3
  • 5常江平,王风,史明,曾少明,叶少波,张忠林.^(89)Sr联合内分泌疗法治疗前列腺癌骨转移的疗效观察[J].医师进修杂志(外科版),2005,28(4):28-29. 被引量:4
  • 6杨宾,翁孝琴,王伟,赵锋.^(89)锶治疗前列腺癌骨转移22例分析[J].中国误诊学杂志,2007,7(1):158-159. 被引量:3
  • 7Robinson RG, Preston DF, Schiefelbein M, et al. Strontium 89 therapy for the palliation of pain due to osseous metastases [ J ]. JAMA, 1995, 274(5) :420-424.
  • 8Dafermou A, Colamussi P, Giganti M, et al. A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer[ J]. Eur J Nucl Med, 2001, 28(7) :788-798.
  • 9Kraeber-Bodere F, Campion L, Rousseau C, et al. Treatment of bone metastases of prostate cancer with strontium-89 chloride : efficacy in relation to the degree of bone involvement [ J ]. Eur J Nucl Med, 2000, 27(10): 1487-1493.

二级参考文献11

  • 1谭天秩.骨转移癌的治疗[A].中华人民共和国卫生部医政司主编.核医学诊断与治疗规范[C].北京:科学出版社,1997.292.295.
  • 2Payne R. Pain management in the patient with prostate cancer[J]. Cancer, 1993, 71(3 Suppl):1131-1137.
  • 3Pons F, Herranz R, Garcia A, et al. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer[J]. Eur J Nucl Med, 1997, 24(10):1210-1214.
  • 4Kraeber-Bodere F, Campion L, Rousseau C, et al. Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement[J]. Eur J Nucl Med, 2000, 27(10):1487-1493.
  • 5Sneller ZW, Hop WC, Carpentier PJ, et al. Prognosis and prostatic volume changes during endocrine management of prostate cancer: a longitudinal study[J]. J Urol, 1992, 147(3 Pt 2): 962-966.
  • 6Robinson RG, Preston DF, Schiefelbein M, et al. Strontium 89 therapy for the palliation of pain due to osseous metastases[J]. JAMA, 1995, 274(5):420-424.
  • 7Porter AT, Vaishampayan N. Strontium-89 in metastasis prostate cancer[J]. Urology Symposium, 1994, 44(7):75-80.
  • 8Dafermou A,Colamussi P,Giganit M,et al.A multicentre observational study of radionu clide therapy in patients withpainful bone metastases of prostate cancer[J].Eur J NuCl Med,2001,289(5):788-798.
  • 9孙达,刘其昌,何刚强.^(89)SrCl_2治疗转移性骨肿瘤的临床应用初析[J].浙江肿瘤,1999,5(4):232-233. 被引量:14
  • 10金凡,周淑贞,陶蓉芳,方茹蓉,项永兵,孙璐,高玉堂.上海市区恶性肿瘤发病趋势1972~1994年[J].肿瘤,1999,19(5):255-258. 被引量:73

共引文献10

同被引文献109

引证文献11

二级引证文献56

;
使用帮助 返回顶部